RUNX1 and myeloid neoplasm: Based on the 2016 World Health Organization classification [38], patients had therapy‐related myeloid neoplasms (22.0%), AML with mutated NPM1 (19.2%), AML with myelodysplasia‐related changes (17.8%), AML with mutated RUNX1 (17.8%), or AML not otherwise specified (15.1%); other categories included core‐binding factor AML (2.7%), AML with biallelic CEBPA mutation (2.7%), or myeloid sarcoma (2.7%) (Table S1).